Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network - PubMed (original) (raw)
Clinical Trial
. 1996 Sep 19;335(12):841-7.
doi: 10.1056/NEJM199609193351202.
E Israel, H A Boushey, V M Chinchilli, J V Fahy, J E Fish, S C Lazarus, R F Lemanske, R J Martin, S P Peters, C Sorkness, S J Szefler
Affiliations
- PMID: 8778601
- DOI: 10.1056/NEJM199609193351202
Free article
Clinical Trial
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network
J M Drazen et al. N Engl J Med. 1996.
Free article
Abstract
Background: Inhaled beta-agonists are the most commonly used treatment for asthma, but data suggest that regularly scheduled use of these agents may have deleterious effect on the control of asthma. We compared the effects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chronic, stable asthma.
Methods: In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients). The patients were followed for 16 weeks.
Results: The primary outcome indicator, peak expiratory air flow measured in the morning, did not change significantly during the treatment period in the scheduled (416 liters per minute after the run-in period and 414 liters per minute after the treatment period) or the as-needed (424 liters per minute at both times) treatment groups (P=0.71). There were no significant differences between the two groups in peak flow variability, forced expiratory volume in one second, the number of puffs of supplemental albuterol needed, asthma symptoms, asthma quality-of-life score, or airway responsiveness to methacholine. The statistically significant differences between the groups in evening peak flow and in the short-term bronchodilator response to inhaled albuterol were small and judged to be clinically unimportant.
Conclusions: In patients with mild asthma, neither deleterious nor beneficial effects derived from the regular use of inhaled albuterol beyond those derived from use of the drug as needed. Inhaled albuterol should be prescribed for patients with mild asthma on an as-needed basis.
Comment in
- ACP J Club. 1997 Jan-Feb;126(1):18
- Inhaled beta 2-agonists in the treatment of asthma.
O'Byrne PM, Kerstjens HA. O'Byrne PM, et al. N Engl J Med. 1996 Sep 19;335(12):886-8. doi: 10.1056/NEJM199609193351211. N Engl J Med. 1996. PMID: 8778610 No abstract available. - Albuterol in mild asthma.
Suissa S, Ernst P. Suissa S, et al. N Engl J Med. 1997 Mar 6;336(10):729; author reply 730. doi: 10.1056/NEJM199703063361013. N Engl J Med. 1997. PMID: 9045048 No abstract available. - Albuterol in mild asthma.
Zahger D. Zahger D. N Engl J Med. 1997 Mar 6;336(10):729-30; author reply 730. N Engl J Med. 1997. PMID: 9045049 No abstract available.
Similar articles
- A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.
Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW, et al. Pearlman DS, et al. N Engl J Med. 1992 Nov 12;327(20):1420-5. doi: 10.1056/NEJM199211123272004. N Engl J Med. 1992. PMID: 1357554 Clinical Trial. - Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, Prillaman B, Shah T. Pearlman DS, et al. Ann Allergy Asthma Immunol. 1999 Mar;82(3):257-65. doi: 10.1016/S1081-1206(10)62606-3. Ann Allergy Asthma Immunol. 1999. PMID: 10094216 Clinical Trial. - Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.
Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Israel E, et al. Lancet. 2004 Oct 23-29;364(9444):1505-12. doi: 10.1016/S0140-6736(04)17273-5. Lancet. 2004. PMID: 15500895 Clinical Trial. - [The management of chronic asthma with inhaled beta 2 agonists--regular use? symptomatic use?].
Kitamura S, Sugama Y. Kitamura S, et al. Nihon Rinsho. 1996 Nov;54(11):3078-80. Nihon Rinsho. 1996. PMID: 8950958 Review. Japanese. - [Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
Ogawa C, Sano Y. Ogawa C, et al. Nihon Rinsho. 1996 Nov;54(11):3081-6. Nihon Rinsho. 1996. PMID: 8950959 Review. Japanese.
Cited by
- Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness.
Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, Liggett SB. Drysdale CM, et al. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10483-8. doi: 10.1073/pnas.97.19.10483. Proc Natl Acad Sci U S A. 2000. PMID: 10984540 Free PMC article. - beta-Adrenergic receptor polymorphisms and response to salmeterol.
Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, Israel E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Wechsler ME, et al. Am J Respir Crit Care Med. 2006 Mar 1;173(5):519-26. doi: 10.1164/rccm.200509-1519OC. Epub 2005 Dec 1. Am J Respir Crit Care Med. 2006. PMID: 16322642 Free PMC article. Clinical Trial. - Asthma outcomes: exacerbations.
Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA Jr, Gern J, Heymann PW, Martinez FD, Mauger D, Teague WG, Blaisdell C. Fuhlbrigge A, et al. J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S34-48. doi: 10.1016/j.jaci.2011.12.983. J Allergy Clin Immunol. 2012. PMID: 22386508 Free PMC article. Review. - NHLBI ASTHMA NETWORKS: IMPROVING PATIENT CARE, MOVING TOWARD PERSONALIZED MEDICINE.
Peters SP. Peters SP. Trans Am Clin Climatol Assoc. 2022;132:44-60. Trans Am Clin Climatol Assoc. 2022. PMID: 36196171 Free PMC article. - Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment.
Walters EH, Walters J. Walters EH, et al. Cochrane Database Syst Rev. 2000;2003(4):CD001285. doi: 10.1002/14651858.CD001285. Cochrane Database Syst Rev. 2000. PMID: 11034709 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical